$ALNY news
The latest ALNY stock news: headlines, filings, AI summaries and sentiment for $ALNY, updated around the clock.
- ALNYLAM PHARMACEUTICALS, INC. - 8-K Filing
- Truist Downgrades Alnylam Pharmaceuticals to Hold Due to Amvuttra Sales Uncertainty
- Bernstein Downgrades Alnylam Pharmaceuticals to Market Perform
- Alnylam Pharmaceuticals Projects $4.2B–$4.5B in 2026 TTR Sales Amid Q3 Revenue Growth
- Alnylam Pharmaceuticals Reports Q3 2026 Revenue Growth Driven by TTR Franchise
- Alnylam Pharmaceuticals Shares Drop 18% Despite Q3 Earnings Beat Due to Slowing US Sales
- ALNYLAM PHARMACEUTICALS, INC. - 10-Q Filing
- ALNYLAM PHARMACEUTICALS, INC. - 8-K Filing
- Alnylam Pharmaceuticals Scheduled to Report Q3 2026 Earnings
- Alger Russell Innovation Index Updates for Third Quarter 2026
- Alnylam Pharmaceuticals Underperformed Amid Clinical Trial Concerns
- Alnylam Shares Drop After AstraZeneca Posts Negative Trial Data
- Alnylam Shares Drop Nearly 30% After Earnings Report and Guidance Cut
- Alnylam Pharma Reports Q2 2026 Earnings with Strong Revenue Growth
- Alnylam Pharmaceuticals Cuts Revenue Guidance Amid Market Headwinds
- ALNYLAM PHARMACEUTICALS, INC. - 10-Q Filing
- ALNYLAM PHARMACEUTICALS, INC. - 8-K Filing
- Alnylam's Record Quarter Fails to Boost Valuation
- William Blair Initiates Coverage of Zura Bio with Outperform Rating
- AstraZeneca and Ionis Pharmaceuticals' Phase 3 Trial Failure Impacts Biotech Market Dynamics
- Morgan Stanley Raises Price Target for Alnylam Pharmaceuticals
- Alnylam Expands RNAi Therapeutics Commercialization into Four Nordic Countries
- Stocks Making Significant Moves Midday: Alnylam, Blackstone, Broadcom, Five Below and Others
- Alnylam Pharmaceuticals partners with Inceptive Nucleics on AI-driven RNAi therapy development
- Alnylam Pharmaceuticals Reports Record Q1 Revenue Driven by AMVUTTRA Growth
- Alnylam Pharmaceuticals Reports Strong Q1 2026 Earnings with Record Revenue
- Alnylam Pharmaceuticals Reports Strong Q1 Earnings with Revenue Growth and Pipeline Expansion
- Alnylam Pharmaceuticals Reports Strong First-Quarter Sales for Amvuttra
- Alnylam Pharmaceuticals Advances Diabetes Drug Into Phase 2 Trial
- Agios (AGIO) Reports Q2 2025 Earnings with Revenue Growth and Pipeline Advancement
- BXMT Q2 2025 Earnings Call Highlights